NCT04906070 is a NA clinical trial of HB-001 in Breast Cancer, sponsored by Hekabio.

Who is sponsoring NCT04906070?

NCT04906070 is sponsored by Hekabio.

What drugs are being tested in NCT04906070?

Interventions in NCT04906070: HB-001.

What condition does NCT04906070 study?

NCT04906070 studies Breast Cancer, Head and Neck Cancer.

Is NCT04906070 still recruiting?

NCT04906070 is currently completed. Last updated 3 June 2022.

Last reviewed 2022-06-03 · How we verify

NCT04906070

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan

Completed NA Last updated 3 June 2022

What this trial tests

NA trial testing HB-001 in Breast Cancer in 14 participants. Completed in 27 May 2022.

Timeline

25 May 2019

Primary endpoint
31 March 2022

27 May 2022

Quick facts

Lead sponsor	Hekabio
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	25 May 2019
Primary completion	31 March 2022
Estimated completion	27 May 2022
Sites	4 locations across Japan

Drugs / interventions tested

HB-001

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Hekabio

Who can join

18 and older, any sex, with Breast Cancer or Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An intratumoral alpha particle based approach for cancer treatment using diffusion alpha-emitting radiation therapy (DaRT)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dual targeting with <sup>224</sup>Ra/<sup>212</sup>Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach.
Juzeniene A, Stenberg VY, Bruland ØS, Revheim ME, et al · · 2022 · cited 8× · PMID 36733936 · DOI 10.3389/fmed.2022.1051825

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04906070 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hekabio
Last refreshed: 3 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04906070.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing